Imalux closes $5.1m series C:
This article was originally published in Clinica
Executive Summary
Imalux, a Cleveland, Ohio company developing an imaging system based on optical coherence tomography, has raised $5.1m in an oversubscribed series C round. The funds, which included $2.5m of bridge financing, came from lead investors Early Stage Partners, ElectroSonics Medical, Reservoir Venture Partners and Symark, as well as over 20 existing and new investors. Imalux said it will use the proceeds to add a further 10-20 units of its Niris imaging system in the US and Europe for clinical validation (there are already over 20 systems installed worldwide), and to support multi-centre studies of the system on bladder cancer patients. The Niris system uses near-infrared light to create real-time images that reveal changes in the stratified structure of tissue.
You may also be interested in...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.